Date: 2012-03-30
Type of information: Fundraising
Company: Immunogenes (Switzerland - Hungary)
Investors: LSWorks LLC (USA)
PolyTechnos Venture Partners (Germany)
majority of the company’s existing investors
Amount: CHF 1 million (€0.83 million)
Funding type: financing round
Planned used: Proceeds of the funding will be used to continue the commercialization of the company’s IMGMouse and IMGRabbit technologies that improve the immune response allowing the development of antibodies against difficult targets for both therapeutic and diagnostic purposes. The company believes that this financing, combined with existing cash on hand, will be sufficient to fund operations through early 2014.
Others: ImmunoGenes AG, a biopharmaceutical company focused on the generation of transgenic animals for antibody development, has closed a CHF 1 million financing round. The financing is being led by LSWorks LLC and PolyTechnos Venture Partners and includes the majority of the company’s existing investors.
Therapeutic area: Technology - Services
